The global botulinum toxin market size was valued at USD 11.1 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 9.8% from 2024 to 2030. Botulinum toxin is a protein and neurotoxin produced by the bacterium clostridium botulinum. The toxin is a selective blocker of acetylcholine released from nerves, which blocks neural transmission from the nerves when injected into muscle. Botulinum toxin is one of the most exceptional substances encountered in medicine and science. The adoption of botulinum toxin in cosmetology has grown rapidly over the decade, and at present it is one of the most common and widely performed aesthetic procedures in the world. The increasing concern for aesthetic features in developed and developing regions has led to an increase in the number of cosmetic procedures.

The availability of a variety of botulinum toxin products such as botox, xeomin, dysport, and others will accelerate the market growth. The increasing usage of botulinum toxin injection in several aesthetic procedures including the treatment of glabellar lines, chemical browlift, forehead lines, and others is expected to boost the botulinum toxin industry growth over the coming years. Presently, a few products of botulinum toxin - Type-A and only one product of Type-B (Myobloc) are commercially available in the market.

Gather more insights about the market drivers, restrains and growth of the Botulinum Toxin Market

Detailed Segmentation

End-use Insights

Based on end-use, the market is segmented into hospitals, dermatology clinics, and spas & cosmetic clinics. Cosmetic centers and medspas accounted for the largest market share of 44.5% in 2023. The higher preference for aesthetic procedures in dermatology clinics and cosmetic centers and medspas is significantly contributing to the segmental growth. The segment is likely to grow with a CAGR of 10.2%. Plastic surgeons and medical spa owners are seeing an increase in customers. In addition, the rising number of medical cosmetic centers and medspas in regions like Asia Pacific are contributing to the market growth.

Product Type Insights

The botulinum toxin-type- A segment exhibited the largest revenue share of 98.8% in 2023. Botulinum toxin A is anticipated to grow at a significant rate due to rise in customer preference owing to advantages including minimal pain, no blood loss, and lack of scarring during the procedure. Botulinum toxin type-A has been increasingly utilized to treat chronic migraine, tension-type headache, and other primary neurological disorders.

Regional Insights

North America accounted for a significant revenue share of 46.9% in 2023 and is anticipated to reach USD 5.1 billion by 2030 owing to increasing disposable income and growing number of cosmetic procedures. For instance, in 2019, as per the American Society of Plastic Surgeons (ASPS), 1.3 million surgeries were performed with botulinum toxin products. Thus, increasing use of botulinum toxin products in various cosmetic procedures performed in the region will stimulate the North America botulinum toxin industry growth.

Application Insights

Based on application, botulinum toxin sector is segmented into aesthetic and therapeutic applications. The aesthetic segment is expected to witness a significant CAGR of 10.2% during the forecast period. Botulinum toxin (BoNT), a bacterially produced neurotoxin, is a mainstay in the cosmetology armamentarium. The rising consciousness for aesthetic appearance and rising technological advancements in developed and developing countries has led to an increase in the number of cosmetic surgeries.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global contrast media injectors market size was valued at USD 1.27 billion in 2023 and is projected to grow at a CAGR of 7.50% from 2024 to 2030.

• The global patient monitoring devices market size was valued at USD 51.1 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 7.7% from 2023 to 2030.

Key Companies profiled:

• Ipsen Group
• Allergen, Inc.
• Metabiologics
• Merz Pharma
• US Worldmeds
• Evolus
• Galderma
• Lanzhou Institute of Biological Products

Botulinum Toxin Market Segmentation

Grand View Research has segmented the global botulinum toxin market report based on product type, application, end-use, and region:

Botulinum Toxin Product Type Outlook (Revenue, USD Billion, 2018 - 2030)
• Type A
o Botox
o Dysport
o Xeomin
o Others
• Type B

Botulinum Toxin Application Outlook (Revenue, USD Billion, 2018 - 2030)
• Therapeutic
o Chronic Migraine
o Overactive Bladder
o Cervical Dystonia
o Spasticity
o Others
• Aesthetic
o Glabellar Lines
o Crow’s Feet
o Forehead Lines
o Others

Botulinum Toxin End-use Outlook (Revenue, USD Billion, 2018 - 2030)
• Hospitals
• Dermatology Clinics
• Cosmetic Centers and Medspas

Botulinum Toxin Regional Outlook (Revenue, USD Billion, 2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o India
o Japan
o China
o South Korea
o Australia
o Thailand
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East & Africa
o South Africa
o Saudi Arabia
o UAE
o Kuwait

Order a free sample PDF of the Botulinum Toxin Market Intelligence Study, published by Grand View Research.